secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0000950170-24-058706
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon Q1 net loss $10.3M ($0.34/share); cash $42.9M; $50M private placement
----------------------------------------------------------------------------

- Net loss of $10.3M ($0.34 diluted EPS) vs $10.8M loss ($0.75 EPS) in Q1 2023.
- Cash, cash equivalents & short-term investments $42.9M at quarter end, excluding $50M private placement.
- Completed oversubscribed $50M private placement at $2.37/share with institutional investors.
- First patient dosed in investigator-led islet cell transplant trial with tegoprubart for type 1 diabetes.
- Phase 2 BESTOW trial (tegoprubart vs tacrolimus) enrolled 12th participant; full enrollment expected end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000095017024058706/0000950170-24-058706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000095017024058706/eldn-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-058706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer